How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH.

[1]  D. Mann.  Recent Insights into the Role of Tumor Necrosis Factor in the Failing Heart , 2001, Heart Failure Reviews.

[2]  Douglas L Mann,et al.  Inflammatory mediators and the failing heart: past, present, and the foreseeable future. , 2002, Circulation research.

[3]  John C. Davis,et al.  Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. , 2002, The New England journal of medicine.

[4]  H. Zeidler,et al.  Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial , 2002, The Lancet.

[5]  S. Fichtlscherer,et al.  Tumor Necrosis Factor Antagonism With Etanercept Improves Systemic Endothelial Vasoreactivity in Patients With Advanced Heart Failure , 2001, Circulation.

[6]  A. Zinsmeister,et al.  Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. , 2001, Gastroenterology.

[7]  Pål Aukrust,et al.  Cytokines as new treatment targets in chronic heart failure , 2001, Current controlled trials in cardiovascular medicine.

[8]  P. Poole‐Wilson,et al.  The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure. , 2001, International journal of cardiology.

[9]  P. Theodossiadis,et al.  Effect of infliximab on sight-threatening panuveitis in Behcet's disease , 2001, The Lancet.

[10]  U. Chaudhari,et al.  Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial , 2001, The Lancet.

[11]  Anita Deswal,et al.  Cytokines and Cytokine Receptors in Advanced Heart Failure: An Analysis of the Cytokine Database from the Vesnarinone Trial (VEST) , 2001, Circulation.

[12]  A. Coats.  Life, quality of life and choice in an ageing society. , 2001, International journal of cardiology.

[13]  B. Bozkurt,et al.  Results of Targeted Anti–Tumor Necrosis Factor Therapy With Etanercept (ENBREL) in Patients With Advanced Heart Failure , 2001, Circulation.

[14]  S. Anker,et al.  Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure , 2000, Circulation.

[15]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[16]  Richard W. Martin,et al.  A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. , 2000, The New England journal of medicine.

[17]  D. Mann,et al.  Cytokines as emerging targets in the treatment of heart failure. , 2000, Trends in cardiovascular medicine.

[18]  S. Anker,et al.  The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1. , 2000, International journal of cardiology.

[19]  A. Coats.  Heart Failure 99 -- the MOXCON story. , 1999, International journal of cardiology.

[20]  B. Bozkurt,et al.  Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. , 1999, Circulation.

[21]  P. Rutgeerts,et al.  Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.

[22]  P. Ponikowski,et al.  Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. , 1999, European heart journal.

[23]  J. Kremer,et al.  A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.

[24]  P. Poole‐Wilson,et al.  Uric acid in chronic heart failure: a marker of chronic inflammation. , 1998, European heart journal.

[25]  S. Nasraway,et al.  Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock , 1998, The Lancet.

[26]  P. Poole‐Wilson,et al.  Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure. , 1998, QJM : monthly journal of the Association of Physicians.

[27]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[28]  P. Ponikowski,et al.  Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. , 1997, Circulation.

[29]  B. Bozkurt,et al.  Basic mechanisms in heart failure: the cytokine hypothesis. , 1996, Journal of cardiac failure.

[30]  J. Carlet,et al.  INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. , 1996, Critical care medicine.

[31]  S. Opal,et al.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. , 1996, The New England journal of medicine.

[32]  O. Febo,et al.  Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. , 1995, Circulation.